Yazar "Yazici, M." seçeneğine göre listele
Listeleniyor 1 - 9 / 9
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Discordance between insulin resistance and metabolic syndrome(Elsevier Ireland Ltd, 2006) Onat, A.; Hergenc, G.; Turkmen, S.; Yazici, M.; Sari, I.; Can, G.Öğe THE IMPACT OF PIOGLITAZONE THERAPY ON GLYCEMIC CONTROL, BLOOD PRESSURE AND INFLAMMATORY MARKERS IN PATIENTS WITH DIABETES MELLITUS(Editura Acad Romane, 2010) Ordu, S.; Gungor, A.; Yuksel, H.; Alemdar, R.; Ozhan, H.; Yazici, M.; Albayrak, S.Aim. The aim of our study was to investigate the effect of pioglitazone on glycemic and blood pressure control, on inflammation markers in diabetic patients. Patients and methods. Forty-nine diabetic patients who had been followed up as outpatients for 2.7 years and HbA1c was >7% were included in the study. The patients had never received thiazolidinedione therapy before. Clinical, metabolic variables, high-sensitive C-reactive protein (hsCRP), homocysteine (HCY) and asymmetric dimethylarginine (ADMA) levels were measured. 30 mg pioglitazone were administered. The patients were followed up for six months and all the measurements were re-evaluated for comparison. Results. Body mass index (BMI) significantly increased after treatment. Fasting glucose, HbA1c and HsCRP were decreased. Insulin resistance was improved and HOMA-IR index was decreased after pioglitazone treatment [8 (+/- 6.5) vs 4(+/- 3.1); p<0.00011. Pioglitazone improved lipid metabolism. Mean total cholesterol and LDL cholesterol levels were decreased and HDL cholesterol was increased after treatment. The decrease in triglyceride and homocysteine levels did not reach significance. Mean ADMA level did not change after therapy [0.62 (+/- 0.39) vs 0.61 (+/- 0.44); p=0.85]. Conclusion. Pioglitazone treatment in type 2 DM produced significant improvements in measures of glycemic control, plasma lipids, blood pressure and homocysteine levels. Pioglitazone had no influence on ADMA levels.Öğe Influences of new risk markers on the severity of coronary atherosclerosis in patients with different risk profiles(Blackwell Publishing, 2006) Guler, S.; Yavuz, O.; Yavuz, M. T.; Yazici, M.; Ozhan, H.; Coskun, A.; Albayrak, S.Öğe Interaction between Chlamydia pneumoniae, inflammation and risk factors in patients with severe coronary stenosis(Blackwell Publishing, 2006) Yavuz, M. T.; Yavuz, O.; Yazici, M.; Guler, S.; Ozhan, H.; Albayrak, S.; Coskun, A.Öğe Obstructive sleep apnea syndrome in Turkish adults(Elsevier Ireland Ltd, 2007) Hergenc, G.; Onat, A.; Uyarel, H.; Yazici, M.; Tuncer, M.; Dogan, Y.; Rasche, K.Öğe Predictors of abdominal obesity and high susceptibility of cardiometabolic risk to its increments among Turkish women: A prospective population-based study(Elsevier Ireland Ltd, 2007) Onat, A.; Sari, I.; Hergenc, Q.; Yazici, M.; Uyarel, H.; Can, G.; Sansoy, V.Öğe The relation between serum high sensitive CRP levels and angiographically documented coronary artery disease(Blackwell Publishing, 2006) Albayrak, E.; Yavuz, M.; Yazici, M.; Ozhan, H.; Erbilen, E.; Yavuz, O.; Kaya, A.Öğe Serum apolipoprotein B predicts hypertension, dyslipidemia, metabolic syndrome and, in women, diabetes(Amer Assoc Clinical Chemistry, 2007) Hergenc, G.; Onat, A.; Can, G.; Yazici, M.; Karabulut, A.; Albayrak, S.Öğe Serum total and HDL-phospholipid levels in a population based study and relation to risk of metabolic yndrome and coronary disease(Elsevier Ireland Ltd, 2006) Hergenc, G.; Onat, A.; Turkmen, S.; Yazici, M.; Sari, I.; Can, G.
